Extending the studies outlined above, ours is the first study to show the prognostic relevance of RUNX1 expression in CN-AML patients and that RUNX1high is associated with poorer OS and EFS in CN-AML patients. The gene discussed is RUNX1; the disease is acute myeloid leukemia.